Drug intelligence / Profile preview

camylofin dihydrochloride

Development stage
Unknown
Lead developer
Abbott
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

Camylofin dihydrochloride is a synthetic antispasmodic agent used to alleviate smooth muscle spasms in the gastrointestinal, biliary, and genitourinary tracts. It functions through a dual mechanism of action: acting as a competitive antagonist at muscarinic acetylcholine receptors (anticholinergic effect) and exerting a direct papaverine-like relaxant effect on smooth muscle cells. This dual action makes it effective for treating conditions such as intestinal colic, biliary colic, renal colic, and spasmodic dysmenorrhea. It is widely utilized in generic formulations, particularly in the Indian pharmaceutical market, and is often administered orally or via intramuscular injection. The drug was originally developed by Boehringer Ingelheim and is now produced by numerous generic manufacturers.

Brand names
AvafortanAnafortanCamyloSpasmonil
Other names
camylofincamylofinecamylofinum
02

Targets

mAChR (Muscarinic acetylcholine receptors)PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on camylofin dihydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on camylofin dihydrochloride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call